Our innovation is powered by continuous investment in scientific research and clinical discovery. We make sure the benefits of our product are thoroughly studied, and all claims are backed by a strong body of evidence – from ingredient-level research to clinical trials on the finished formula.
The result? AG1 doesn’t just feel different – the impact is measurable.
AG1 has undergone multiple gold-standard clinical trials – repeatedly proving its effectiveness in supporting nutrient absorption across different populations and study designs.
Tested for impact on:
AG1 has undergone multiple gold-standard clinical trials – repeatedly proving its effectiveness in supporting nutrient absorption across different populations and study designs.
Tested for impact on:
AG1 decreases Homocystein levels.ᵃ
AG1 increases Vitamin C levelsᵃ
Over 10x average increase in friendly bacteria in the gut.ᵃ⁻ᶜ
Thiamine levels were significantly increased within 30 minutes of drinking AG1.ᵈ
a. In a triple-blind, randomised, placebo-controlled parallel-designed clinical trial evaluating nutrient biomarkers and microbiome shifts in 105 healthy adults ages 20-59 over the course of 12 weeks.
b. In a double-blind, randomised, placebo-controlled 2-week cross-over clinical trial assessing microbiome shifts in 20 active adults ages 19-37.
c. In a double-blind, randomised, placebo-controlled 2-week cross-over clinical trial assessing microbiome shifts of 24 healthy adults with occasional GI distress ages 26-59.
d. In a double-blind, randomised, placebo-controlled cross-over clinical trial assessing bioavailability in 16 healthy adults ages 18-42 over the course of 8 hours.
The studies were conducted on a similar version of AG1's continually evolving formulation. The transferability of the study results is ensured because of comparable ingredients and amounts.
There are many ways to study how nutrition affects the body. In our clinical research, we use advanced tools and technologies – together with our academic and clinical partners – to explore the connection between nutrient intake and microbiome composition.
Our Team
Our in-house team of clinicians and scientists bring diverse expertise across nutrition, metabolism, microbiome, and related fields. We also collaborate with independent experts, academic institutions, and clinical partners to advance research and expand our understanding with cutting-edge technology.
We’re proud to share that four clinical trials – rigorously designed, randomised, placebo-controlled trials – on the AG1 formula have been completed. This is a major milestone in our scientific journey and one that underscores our long-standing commitment to evidence-based innovation.
Just like the trials themselves, the clinical research lifecycle is also rigorous, and it can be lengthy.
The process of undertaking a trial, analysing the results, and publishing them can take years. But we know it’s worth the wait, because we’re committed to advancing science – not just for the sake of innovation, but to contribute meaningfully to advancing the science of nutrition and the microbiome forward.
At AG1, science is at the heart of everything we do. Our commitment to research goes beyond any single formulation – we invest in rigorous, ongoing clinical studies to explore the role of foundational nutrition in overall health.
Beyond sharing our findings, we work with leading researchers to submit study manuscripts to peer-reviewed scientific journals – contributing to the broader scientific dialogue on the vital role of nutrition and the microbiome in overall health. To date, our peer-reviewed publications include both literature reviews and research on the AG1 original formula, which you can explore here.
In addition, multiple clinical studies on AG1 have been completed, and several abstracts have been accepted at upcoming national scientific conferences. As they are presented and published, we will update this page. In parallel, we are also working on several manuscripts which will be submitted to peer reviewed journals and published here upon acceptance.
The effects of AG1® supplementation on the gut microbiome of healthy adults: a randomized, double-blind, placebo-controlled clinical trial
This study investigated the effects of AG1® supplementation on the gut microbiome, GI tolerability, and clinical safety markers in healthy adults. After four weeks, AG1® enriched beneficial probiotic taxa, showed a potential improvement in digestive quality of life, and did not negatively impact stool consistency, bowel frequency, or clinical safety markers, demonstrating its safety for daily use.
Foundational Nutrition: Implications for Human Health
Human nutrition, and what can be considered “ideal” nutrition, is a complex, multi-faceted topic which many researchers and practitioners deliberate. While some attest that basic human nutrition is relatively understood, it is undeniable that a global nutritional problem persists.
Nutrient synergy: definition, evidence, and future directions
Nutrient synergy refers to the concept that the combined effects of two or more nutrients working together have a greater physiological impact on the body than when each nutrient is consumed individually.
The Novel Synbiotic, AG1®, Increases Short-Chained Fatty Acid Production in the Simulator of Human Intestinal Microbial Ecosystem (SHIME) Model®
Recently, there is growing usage of prebiotics and probiotics as dietary supplements due to their purported health benefits. AG1® (AG1) is a novel foundational nutrition supplement which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms.
AG1®, a Novel Synbiotic, Demonstrates Superior Mineral Bioaccessibility and Bioavailability Compared to a Tablet Multivitamin and Mineral Supplement Using an In Vitro Model of the Upper Gastrointestinal Tract
While traditional multivitamin and mineral (MVM) supplements generally come in tablet form, new powder forms of MVM supplements are available with theoretically higher bioavailability relative to tablet MVM supplements. which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms. Recently, there is growing usage of prebiotics and probiotics as dietary supplements due to their purported health benefits. AG1® (AG1) is a novel foundational nutrition supplement which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms. Recently, there is growing usage of prebiotics and probiotics as dietary supplements due to their purported health benefits. AG1® (AG1) is a novel foundational nutrition supplement which contains vitamins, minerals, phytonutrients, wholefood concentrates, adaptogens, and functional mushrooms.
AG1® Induces a Favorable Impact on Gut Microbial Structure and Functionality in the Simulator of Human Intestinal Microbial Ecosystem® Model
The study using the SHIME® model demonstrated that AG1® had a significant impact on the composition of the human gut microbiota, leading to differential enrichment of bacterial taxa and metabolic pathways, suggesting potential favorable effects on gut microbial composition following AG1® supplementation. Kirby et al 2024.
AG1®, a Novel Synbiotic, Maintains Gut Barrier Function following Inflammatory Challenge in a Caco-2/THP1-Blue™ Co-Culture Model
This in vitro study assessed the impact of AG1, a synbiotic supplement, on gastrointestinal (GI) permeability following an inflammatory challenge. Using a human GI tract model, AG1 was found to significantly improve transepithelial electrical resistance (TEER), suggesting protective effects on GI permeability compared to a control. No significant differences in inflammatory markers were observed, and the beneficial effects may be driven by short-chain fatty acid (SCFA) production from AG1’s prebiotic and probiotic components.
Changes in the fecal polar metabolome due to AG1 supplementation in the SHIME® model: A proof of principle study
Metabolomics is a critical approach to fully understand the metabolic repercussions of a nutritional supplement on the gut microbiota. Here, a proof of principle study was conducted via a metabolomic survey of polar metabolites to explore the effect of AG1 on the metabolic output of the human gut microbiota, in vitro, using the Simulator of the Human Intestinal Microbial Ecosystem® (SHIME)
AG1 has been studied across multiple clinical trials, consistently demonstrating its effectiveness in increasing nutrient levels and enriching the microbiome.
